FISCAL NOTE
Date Requested: January 21, 2026
Time Requested: 03:42 PM |
| Agency: |
Health, WV Department of |
|---|
| CBD Number: |
Version: |
Bill Number: |
Resolution Number: |
| 1162 |
Introduced |
HB4626 |
|
|---|
| CBD Subject: |
Health |
|---|
|
FUND(S):
'0407 - Central Office General Administrative Fund
Sources of Revenue:
General Fund
Legislation creates:
Fiscal Note Summary
Effect this measure will have on costs and revenues of state government.
The purpose of this bill is to establish a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine for the purpose of securing the Administration’s approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
While, the Department has processes in place to provide and administer a grant program for USDA Drug development trial, the Department cannot currently estimate the cost associated with an actual trial as the Department does not regulate pharma and has no point of reference on drug clinical trials. Therefore, grant process could be developed, but based on the applications, funding would need provided to cover the cost of the trial. Some online information indicated that clinical trials for FDA-approved drugs have a median cost of approximately $19,000,000 per trial, with development costs ranging from $1-$3 billion per drug.
Funding for this initiative would need to be appropriated or otherwise identified.
The cost for the Department should be minimal for the creation and functions of the selection committee and establishment of drug development trial sites. Any employee time for scheduling and attending meetings, research, drafting documents, etc. would be covered under current responsibilities and existing staff.
Fiscal Note Detail
| Effect of Proposal |
Fiscal Year |
2026
Increase/Decrease
(use"-") |
2027
Increase/Decrease
(use"-") |
Fiscal Year
(Upon Full
Implementation) |
| 1. Estmated Total Cost |
0 |
0 |
0 |
| Personal Services |
0 |
0 |
0 |
| Current Expenses |
0 |
0 |
0 |
| Repairs and Alterations |
0 |
0 |
0 |
| Assets |
0 |
0 |
0 |
| Other |
0 |
0 |
0 |
| 2. Estimated Total Revenues |
0 |
0 |
0 |
Explanation of above estimates (including long-range effect):
Please explain increases and decreases in personal services, current expenses, repairs and alterations, assets, other costs and revenues, including assumptions and data sources and delineation between start-up and ongoing costs. Please also include a long-range schedule of costs and revenues if fiscal impact is expected to vary in future years.
Memorandum
Please identify any areas of vagueness, technical defects, reasons a bill would not have a fiscal impact, and/or any special issues not captured elsewhere on this form.
Person submitting Fiscal Note: Arvin Singh, Secretary, EdD, MBA, MPH, MS, FACHE
Email Address: osafiscalnotes@wv.gov